Dale Christensen, PhD
Scientific Advisory Board
Dr. Christensen joins APIE-Therapeutics as member of the Scientific Advisory Board. Dr. Dale Christensen is an experienced biotech executive with extensive expertise managing pre-clinical discovery and pharmacology efforts across respiratory, inflammation, CNS, anti-infective, and oncology indications. Dale expertise comprises strategic guidance from lead generation (across a wide range of therapeutics areas) through preclinical studies to Proof of Concept (POC) clinical trials. Dale has successfully provided not only strategic oversight but also effective execution of preclinical studies translation into approval of IND submissions, including clinical trial design and early clinical trial execution; biomarker development; toxicology study design and execution; and CMC activities for multiple compounds. Dale has also been involved in several biopharma entrepreneurial ventures most recently raising $21M in Series A funding from angel investors and $4.5M in non-dilutive funding for 4-four new startup companies and have aided in the successful IPO for companies. Dale has also demonstrated his ability to add value to entrepreneurial ventures and start-up by negotiating strategic partnerships with large pharma and excellence in managing external alliances. Dr. Christensen is currently an Adjunct Associate Professor of Medicine (Hematology) at Duke University Medical Center and has 20+ years of research experience at the interface of chemistry and biology, with Executive Senior positions at Oncotide, Cognosci, Affinergy Inc., Aryzun Pharmaceuticals, and KaroBio USA, formerly Novalon Pharmaceuticals.
Dr. Christensen received his B.S. in Chemistry from Utah State University, and a Ph.D. in Organic Chemistry from the University of Utah. He was an NIH Postdoctoral Fellow at Texas A&M University. He has published many papers and is an inventor on numerous patents and patent applications in drug discovery.